Improvement bioavailability of silymarin ameliorates severe dyslipidemia associated with metabolic syndrome
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- Keywords
- ABC transporters, CYP4A, CYP7A1, HDL-cholesterol,
- MeSH
- ATP-Binding Cassette Transporters metabolism MeSH
- Biological Availability MeSH
- Cholesterol 7-alpha-Hydroxylase metabolism MeSH
- Cytochrome P-450 CYP4A metabolism MeSH
- Dyslipidemias blood complications drug therapy MeSH
- Liver drug effects enzymology MeSH
- Lipids blood MeSH
- Metabolic Syndrome blood complications drug therapy MeSH
- Rats, Wistar MeSH
- Silymarin pharmacology therapeutic use MeSH
- Blotting, Western MeSH
- Animals MeSH
- Check Tag
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- ATP-Binding Cassette Transporters MeSH
- Cholesterol 7-alpha-Hydroxylase MeSH
- CYP7A1 protein, rat MeSH Browser
- Cytochrome P-450 CYP4A MeSH
- Lipids MeSH
- Silymarin MeSH
1. To compare the effectiveness of different drug forms of silymarin: standardized extract of silymarin (SS), micronized silymarin (MS) and silymarin in the form of phytosome (PS) on dyslipidemia and liver fat accumulation in a model of metabolic syndrome, in non-obese hereditary hypertriglyceridemic rats. The second aim of this study was to slightly uncover the silymarin action on enzymes and proteins involved in cholesterol metabolism and excretion. 2. Silymarin administered to hereditary hypertriglyceridemic rats as dietary supplements (1%) for 4 weeks significantly lowered the plasma levels of triglycerides, total cholesterol and markedly increased HDL cholesterol level. Western blot analyses showed significant increase in the protein expression of CYP7A1 and CYP4A and increase in protein expression of selected ABC transporters. Silymarin in the form of phytosome and micronized silymarin were more effective forms of silymarin. 3. These findings suggest that silymarin may favorably affect the metabolism of cholesterol and triglycerides in rats with metabolic syndrome. Raising HDL levels suggests potentially important anti-atherogenic effect of silymarin. The changes in expression of cytochromes P450 and ABC transporters involved in cholesterol metabolism and excretion could be partially responsible for the hypolipidemic effect of silymarin.
References provided by Crossref.org
